Home » Our business

Debio 1142

Debio 1142 is an early oncology project with an undisclosed target.

Press Releases

14 April 2011

Debiopharm and Aurigene sign agreement for the development and commercialisation of Debio 1142, a novel inhibitor of an undisclosed oncology pathway

Latest News

15 May 2012 Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland - A drug treatment for prostate cancer and endometriosis

16 February 2012 Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932

09 November 2011 Augurix Diagnostics receives the 2011 ‘Debiopharm /Valais Award’ For its point-of-care diagnostic test for the early detection of Celiac disease

Debiopharm on

© 2012 Debiopharm Group